Ruxolitinib (S) 05 trifluoroacetate 15)/b10-3-

15)/b10-3-

2-7H3/t13-

approximately 58-fold more effective than sodium stibogluconate

Fenretinide treatment improves glucose tolerance and insulin sensitivity as determined by both glucose and insulin tolerance tests

Karlsson JJ

Ruxolitinib (S) 05 trifluoroacetate 15)/b10-3-S Ruxolitinib is a less active enantiomer of Ruxolitinib, a JAK1 2 inhibitor. S Ruxolitinib was initially developed to target the constitutive activation of the JAK STAT pathway. Janus kinases (JAKs) are a family of cytoplasmic tyrosine kinases that mediates signals from the receptors for various cytokines and growth factors that have a key role in haematopoiesis and immune function. Ruxolitinib maintains its anti JAK activity by competitive